Checkpoint Inhibitors news and latest updates

News and Trends 15 Jun 2023

IOME Bio claims breakthrough in cancer research

IOME Bio, a French seed stage biotechnology company focused on overcoming tumor resistance to immune checkpoint inhibition, has published its foundational research by founders Arlene Sharpe and Dennis Kasper in…

June 15, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Mar 2023

Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor

Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for immune checkpoint inhibitor LR 09. LR…

March 3, 2023 - 3 minutesmins - By Jim Cornall

bristol myers squibb immunooncology cancer opdivo psioxus

News and Trends 1 Jul 2016

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster drug with an Oncolytic viral therapy in late-stage cancer patients.…

July 1, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 28 May 2018

Genmab and Janssen Suffer Combination Therapy Setback

Janssen will discontinue a Phase I study testing Danish biotech Genmab's blood cancer blockbuster daratumumab combined with a candidate checkpoint inhibitor in patients with multiple myeloma. Janssen, which obtained the…

May 28, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 1 Feb 2023

Next-generation small molecules hold promise for immunotherapy

By Ian B. Walters, chief executive officer and chairman, Portage Biotech In recent years, PD-1/PD-L1 checkpoint antibody therapies have revolutionized the immuno-oncology landscape and offered cancer patients the hope for…

February 1, 2023 - 3 minutesmins - By External Contributor

News and Trends 20 Jan 2023

DeuterOncology closes financing round to start lung cancer study

DeuterOncology, a clinical-stage drug development company, has closed €5.65 million ($6.1 million) series A financing, to start the phase I clinical study for its lead product DO-2, an improved MET…

January 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

ImaginAb launches trial to study neoadjuvant immunotherapy

ImaginAb Inc., in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated phase II trial. It will explore the efficacy and safety…

December 14, 2022 - 2 minutesmins - By Jim Cornall

immutep checkpoint inhibitor lag 3 cancer

Interview 29 Nov 2022

LAG-3: The next big checkpoint inhibitor target

Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The Australian-French firm Immutep explains why the immune checkpoint target LAG-3…

November 29, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 20 Sep 2022

Regen BioPharma files patent on new RNA/DNA-based approach to cancer immunotherapy

Regen BioPharma, Inc. has filed a provisional patent application with the USPTO entitled "Dual Checkpoint Inhibitor Aptamer Based Therapeutics." The application covers novel compositions of matter capable of acting as…

September 20, 2022 - 2 minutesmins - By Jim Cornall

Patient dosed in phase 1 trial evaluating ATG-018 treatment

News and Trends 16 Aug 2022

Patient dosed in phase 1 trial evaluating treatment for those with tumors and malignancies

The first patient has been dosed in a phase 1 trial evaluating a monotherapy treatment in people with advanced solid tumors and hematologic malignancies in Australia. Antengene Corporation Ltd., is…

August 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 30 Jun 2022

LG Chem renews license triggering $2M payment to Avacta

South Korean clinical stage biopharmaceutical company, LG Chem Life Sciences, has triggered a license renewal fee to UK-based oncology drug company Avacta Group plc. of $2 million. Avacta develops cancer…

June 30, 2022 - 2 minutesmins - By Liza Laws

News and Trends 30 Jun 2021

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with…

June 30, 2021 - 5 minutesmins - By Victor Kotsev

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering